<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467270</url>
  </required_header>
  <id_info>
    <org_study_id>AP24534-14-203</org_study_id>
    <secondary_id>2014‐001617‐12</secondary_id>
    <nct_id>NCT02467270</nct_id>
  </id_info>
  <brief_title>Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses</brief_title>
  <acronym>OPTIC</acronym>
  <official_title>A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ariad Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and characterize the efficacy and safety of ponatinib
      in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) in a
      range of doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, phase 2 trial to characterize the safety and efficacy of
      ponatinib over a range of 3 starting doses. Eligible participants must have chronic phase
      chronic myeloid leukemia (CP-CML) and have demonstrated resistance to treatment or have the
      T315I mutation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with ≤1% BCR-ABL 1IS at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular Response Rates (MRR) at Months 12 and 24</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>MRR is defined as percentage of participants with molecular response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Cytogenetic Response Rates (MCyR) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>MCyR is defined as percentage of participants with cytogenic response where cytogenic response is the presence of 0-35% of Ph+ cells in bone marrow. Response is further defined as partial cytogenetic response (PCyR), complete cytogenetic response (CCyR), or ≤1% BCR ABL(IS) (i.e., MR2), which is equivalent to CCyR.≤1% BCR-ABL 1IS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of MRR</measure>
    <time_frame>From randomization up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Arterial Occlusive Events (AOEs) and Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs)</measure>
    <time_frame>Baseline up to Month 24</time_frame>
    <description>These events will be categorized according to main vasculature affected (cardiovascular, cerebrovascular or peripheral vascular).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Measured by Comparing Frequencies of AEs, SAEs and VOEs, AOEs and VTEs</measure>
    <time_frame>Baseline up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the Relationship Between Steady-state Plasma Ponatinib Exposure [Peak Plasma Concentration (Cmax) and Area-under-the-curve (AUC)] and Safety measures (AOEs and VTEs and any AEs that occur in at least 30 participants)</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the Relationship between Steady-state Plasma Ponatinib Exposure (AUC and Cmax) and Efficacy Measures (including ≤1% BCR-ABL 1IS, MCyR, and MRR</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Myeloid Leukemia, Chronic, Chronic Phase</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ponatinib 45 mg once daily starting dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ponatinib 30 mg once daily starting dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ponatinib 15 mg once daily starting dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ponatinib 45 mg</intervention_name>
    <description>45 mg tablet, taken orally once daily</description>
    <arm_group_label>Cohort A</arm_group_label>
    <other_name>Iclusig</other_name>
    <other_name>AP24534</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ponatinib 30 mg</intervention_name>
    <description>30 mg tablet, taken orally once daily</description>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>Iclusig</other_name>
    <other_name>AP24534</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ponatinib 15 mg</intervention_name>
    <description>15 mg tablet, taken orally once daily</description>
    <arm_group_label>Cohort C</arm_group_label>
    <other_name>Iclusig</other_name>
    <other_name>AP24534</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have Chronic Phase Chronic Myeloid Leukemia (CP-CML) and have received at least two
             prior tyrosine-kinase inhibitor (TKI) therapies and have demonstrated resistance to
             treatment OR have documented history of presence of T3151 mutation after receiving any
             number of prior TKI

             a. The diagnosis of CML will be made using standard hematopathologic and cytogenetic
             criteria; CP-CML will be defined by all of the following: i) &lt; 15% blasts in bone
             marrow ii) &lt; 30% blasts plus promyelocytes in bone marrow iii) &lt; 20% basophils in
             peripheral blood iv) ≥ 100 × 109/L platelets (≥ 100,000/mm^3) v) No evidence of
             extramedullary disease except hepatosplenomegaly vi) No prior diagnosis of accelerated
             phase (AP-CML), and blastic phase (BP-CML) b. Cytogenetic assessment at screening must
             demonstrate the BCR-ABL1 fusion by presence of the t(9;22) Philadelphia chromosome i)
             Variant translocations are only allowed provided they are assessable for cytogenetic
             response utilizing conventional cytogenetic techniques c. Resistance to prior TKI
             therapy is defined as follows (participants must meet at least 1 criterion): i) Three
             months after the initiation of prior TKI therapy: No cytogenetic response (&gt; 95% Ph+)
             or failure to achieve complete hematologic response (CHR) or new mutation ii) Six
             months after the initiation of prior TKI therapy: BCR-ABL1IS &gt;10% and/or Ph+ &gt;65% or
             new mutation iii) Twelve months after the initiation of prior TKI therapy: BCR ABL1IS
             &gt;10% and/or Ph+ &gt;35% or new mutation.

             iv) At any time after the initiation of prior TKI therapy, the development of a new
             BCR-ABL1 kinase domain mutation(s).

             v) At any time after the initiation of prior TKI therapy, the development of new
             clonal evolution vi) At any time after the initiation of prior TKI therapy, the loss
             of CHR, or complete cytogenic response (CCyR), or the confirmed loss of molecular
             response rate (MRR) in 2 consecutive tests, one of which has a BCR-ABL1IS transcript
             level of ≥1% or new mutation d. &gt; 1% of BCR-ABL1IS as shown by real-time polymerase
             chain reaction

          2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          3. Have adequate renal function as defined by the following criterion:

               -  Serum creatinine ≤1.5 × upper limit of normal (ULN) for institution

               -  Estimated creatinine clearance ≥ 30mL/min (Cockcroft-Gault formula)

          4. Have adequate hepatic function as defined by the following criteria:

               -  Total serum bilirubin ≤1.5 × ULN, unless due to Gilbert's syndrome

               -  Alanine transaminase (ALT) ≤2.5 × ULN, or ≤5 × ULN if leukemic infiltration of
                  the liver is present

               -  Aspartate transaminase (AST) ≤2.5 × ULN, or ≤5 × ULN if leukemic infiltration of
                  the liver is present

          5. Have normal pancreatic status as defined by the following criterion:

             a. Serum lipase and amylase ≤ 1.5 × ULN

          6. Have normal QT interval corrected (Frederica) (QTcF) interval on screening
             electrocardiogram (ECG) evaluation, defined as QTcF of ≤ 450 ms in males or ≤ 470 ms
             in females.

          7. Have recovered from toxicities related to prior anticancer therapy to National Cancer
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 grade ≤1.

        Exclusion Criteria:

          1. Have used any approved TKIs or investigational agents within 2 weeks or 6 half-lives
             of the agent, whichever is longer, prior to receiving study drug

          2. Received interferon, cytarabine, or immunotherapy within 14 days, or any other
             cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior
             to receiving the first dose of ponatinib, or have not recovered (&gt; grade 1 by NCI
             CTCAE, version 4.0) from AEs (except alopecia), due to agents previously administered

          3. Have undergone autologous or allogeneic stem cell transplant &lt;60 days prior to
             receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host
             disease (GVHD) or GVHD requiring immunosuppressive therapy or are being considered for
             stem cell transplant within 6-12 months of enrollment (note: ponatinib is not to be
             used as a bridge to stem cell transplant in this trial)

          4. Are taking medications with a known risk of Torsades de Pointes

          5. Have clinically significant, uncontrolled, or active cardiovascular disease,
             specifically including, but not restricted to:

               -  Any history of myocardial infarction (MI), unstable angina, cerebrovascular
                  accident, or Transient Ischemic Attack (TIA)

               -  Any history of peripheral vascular infarction, including visceral infarction

               -  Any revascularization procedure, including the placement of a stent

               -  Congestive heart failure (NYHA class III or IV) within 6 months prior to
                  enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of
                  normal, per local institutional standards, within 6 months prior to enrollment

               -  History of clinically significant (as determined by the treating physician)
                  atrial arrhythmia or any history of ventricular arrhythmia

               -  Venous thromboembolism, including deep venous thrombosis or pulmonary embolism,
                  within 6 months prior to enrollment

          6. Have uncontrolled hypertension (i.e., &gt;150 and &gt;90 for systolic blood pressure (SBP)
             and diastolic blood pressure (DBP) respectively). Participants with hypertension
             should be under treatment at study entry to ensure blood pressure control. Those
             requiring 3 or more antihypertensive medications should be discussed with the medical
             monitor.

          7. Have poorly controlled diabetes defined as HbA1c values of&gt; 7.5%. Participants with
             preexisting, well-controlled diabetes are not excluded.

               -  Additional inclusion/exclusion criteria per protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>844-662-8532</phone>
    <email>globaloncologymedinfo@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope (Site 009)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David S. Snyder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital (Site 058)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vamsi Kota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation Clinic (Site 138)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luke Akard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics (Site 050)</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Usha Perepu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Greenbaum Cancer Center (Site 040)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Baer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System (Site 011)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Moshe Talpaz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute (Site 034)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Schiffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center (Site 235)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lori Maness-Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center (Site 128)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James McCloskey II</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (Site 078)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald O'Neill</last_name>
      <phone>212-639-5810</phone>
    </contact>
    <investigator>
      <last_name>Michael Mauro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University and New York Presbyterian Hospita (Site 006)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Alettie</last_name>
      <phone>212-746-0743</phone>
    </contact>
    <investigator>
      <last_name>Ellen Ritchie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (Site 003)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl M Maxey</last_name>
      <phone>919-668-0657</phone>
    </contact>
    <investigator>
      <last_name>Joseph Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation (Site 004)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Sudipto Mukherjee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (Site 048)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne Liming</last_name>
      <phone>503-494-6865</phone>
    </contact>
    <investigator>
      <last_name>Michael Heinrich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania (Site 013)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Selena Luger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center (Site 005)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jorge E. Cortes, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute (Site 043)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Deiningeri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramos Mejia (Site 826)</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1221</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Merlo</last_name>
      <phone>54 9 11 59586382</phone>
    </contact>
    <investigator>
      <last_name>Elena B Moiraghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FUNDALEU (Site 825)</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aire</state>
        <zip>C1114AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Frau</last_name>
      <phone>54-11-4877-1070</phone>
    </contact>
    <investigator>
      <last_name>Carolina Pavlovsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital (Site 941)</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicki Katsioulas</last_name>
      <phone>61-2-9926-4070</phone>
    </contact>
    <investigator>
      <last_name>Christopher K Arthur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital, Haematology Clinical Trials (Site 951)</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Professor Timothy Peter Hughes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent (Site 756)</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Dr. Lucien Noens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Campus Gasthuisberg (Site 700)</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Dr. Gregor Verhoef</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre (Site 083)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Howard Lipton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital (Site 129)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T IE2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Pascale Guay</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>4912</phone_ext>
    </contact>
    <investigator>
      <last_name>Sarit Assouline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pasqua Hospital (Site 227)</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Haji Chalchal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Salvador (Site 829)</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>7500922</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gianna Capurro</last_name>
      <phone>56-2-25754245</phone>
    </contact>
    <investigator>
      <last_name>Maria Soledad Undurraga Sutton, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clínicas Viña del Mar (Site 828)</name>
      <address>
        <city>Vina del Mar</city>
        <state>Quinta Regin</state>
        <zip>254-0364</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Castagneto</last_name>
      <phone>56-32-2891219</phone>
    </contact>
    <investigator>
      <last_name>Christine Rojas Hopkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital (Site 973)</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Kwong Yok-Lam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomoue (Site 515)</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>prof. Karel Indrak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute of Hematology and Blood Transfusion (UHKT) (Site 516)</name>
      <address>
        <city>Praha 2</city>
        <zip>128 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Vedrova</last_name>
      <phone>+420221977277</phone>
    </contact>
    <investigator>
      <last_name>Hana Klamova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haematologisk Afdeling, Arahus Universitehospital (Site 683)</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Jesper Stentoft, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Finland Central Hospital, Hematological Unit (Site 684)</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>FI 70029 Kuopio</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marita Nurmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Poitiers, Department of Oncology-Hematology and Cell Therapy (Site 954)</name>
      <address>
        <city>Poitiers</city>
        <state>B.p. 577</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Francois Guilhot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez CHRU (Site 952)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037 CEDEX</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Brice</last_name>
      <phone>33320446011</phone>
    </contact>
    <investigator>
      <last_name>Valerie Coiteux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers, Service Maladies du Sang (Site 685)</name>
      <address>
        <city>Angers Cedex 9</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Martine Gardembas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie, Institut Bergonie (Site 772)</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Gabriel Etienne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hotel-Dieu, Service d'Hematologie Clinique (Site 521)</name>
      <address>
        <city>Nantes Cedex</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Viviane Dubruille</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Archet 1 (Site 509)</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine Rigualt</last_name>
      <phone>00334.92.03.62.68</phone>
    </contact>
    <investigator>
      <last_name>Laurence Legros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital - CHU Brabois (Site 953)</name>
      <address>
        <city>Vandoeuvre-les-Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Agnes-Paule Guerci-Bresler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Aachen, AOR (Site 513)</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Holst</last_name>
      <phone>00492418037141</phone>
    </contact>
    <investigator>
      <last_name>Martina Crysandt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsmcdizin Berlin - Charitc (CVK) (Site 701)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Grill</last_name>
      <phone>0049 (0) 30 450 553563</phone>
    </contact>
    <investigator>
      <last_name>Philipp Le Coutre, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essen University Hospital (Site 686)</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Vester</last_name>
      <phone>0049 (0) 201 723-2553</phone>
    </contact>
    <investigator>
      <last_name>Jürgen Novotny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg (Site 527)</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joana Meisenzahl</last_name>
      <phone>0049 (761) 270-32900</phone>
    </contact>
    <investigator>
      <last_name>Nikolas von Bubnoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubertus Wald Tumorzentrum University Cancer Center Hamburg (Site 524)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliane Granzow</last_name>
      <phone>0049 40 7410 57843</phone>
    </contact>
    <investigator>
      <last_name>Philippe Schafhausen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena (Site 946)</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Mathes</last_name>
      <phone>0049 36 41-9 32 54 31</phone>
    </contact>
    <investigator>
      <last_name>Andreas Hochhaus, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg (Site 947)</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Pleil-Losch</last_name>
      <phone>0049(0)621 3836951</phone>
    </contact>
    <investigator>
      <last_name>Susanne Saussele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ulm (Site 694)</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Böltau</last_name>
      <phone>0049 (0) 731/500-67257</phone>
    </contact>
    <investigator>
      <last_name>Frank Stegelmann, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Marche Nord (Site 689)</name>
      <address>
        <city>Pesaro</city>
        <state>Pesaro E Urbino</state>
        <zip>61122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Nardelli</last_name>
      <phone>0039 0721364107</phone>
    </contact>
    <investigator>
      <last_name>Giuseppe Visani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Policlinico (Site 530)</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanna Pappalardo</last_name>
      <phone>0039095/7436261</phone>
    </contact>
    <investigator>
      <last_name>Francesco Di Raimondo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>V.O. Clinica Ematologica (Site 528)</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Attilia Grassi</last_name>
      <phone>0039010 555 3021</phone>
    </contact>
    <investigator>
      <last_name>Marco Gobbi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST San Gerardo Hospital (Site 355)</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dario Cerri</last_name>
      <phone>0039 0392332451</phone>
    </contact>
    <investigator>
      <last_name>Carlo Gambacorti-Passerini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pescara Civil Hospital (Site 688)</name>
      <address>
        <city>Pescara</city>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppina Di Florio</last_name>
      <phone>0039085/4252624</phone>
    </contact>
    <investigator>
      <last_name>Paolo Di Bartolomeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University La Spienza (Site 511)</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrica Arduini</last_name>
      <phone>00390649970595</phone>
    </contact>
    <investigator>
      <last_name>Giuliana Alimena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Borgo Roma - Verona (Site 687)</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgia Barbiero</last_name>
      <phone>0039 045 812 4613</phone>
    </contact>
    <investigator>
      <last_name>Massimiliano Bonifacio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital (Site 414)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seiji Ohshima</last_name>
    </contact>
    <investigator>
      <last_name>Kazuhito Yamamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital (Site 415)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norihiro Sakakibara</last_name>
    </contact>
    <investigator>
      <last_name>Takanori Teshima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Hyogo College of Medicine (Site 429)</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Suzuki</last_name>
    </contact>
    <investigator>
      <last_name>Masaya Okada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital (Site 427)</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takako Ikegami</last_name>
    </contact>
    <investigator>
      <last_name>Yasunori Ueda, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital (Site 422)</name>
      <address>
        <city>Osaka-Sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomoko Kawase</last_name>
    </contact>
    <investigator>
      <last_name>Itaru Matsumura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Jikei University Hospital (Site 428)</name>
      <address>
        <city>Minato</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dai Harada</last_name>
    </contact>
    <investigator>
      <last_name>Shingo Yano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital (Site 423)</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomoko Nishida</last_name>
    </contact>
    <investigator>
      <last_name>Katsuto Takenaka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Kyoto Prefectural University of Medicine (Site 419)</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shigeru Tsukamoto</last_name>
    </contact>
    <investigator>
      <last_name>Masafumi Taniwaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital (Site 418)</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshimitsu Konuma</last_name>
    </contact>
    <investigator>
      <last_name>Yoshinobu Maeda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital (Site 413)</name>
      <address>
        <city>Osaka</city>
        <zip>545-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miyuki Amakawa</last_name>
    </contact>
    <investigator>
      <last_name>Hirohisa Nakamae</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saga University Hospital (Site 420)</name>
      <address>
        <city>Saga</city>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachiko Takemori</last_name>
    </contact>
    <investigator>
      <last_name>Shinya Kimura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center, Saitama Medical University (Site 416)</name>
      <address>
        <city>Saitama</city>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mashu Morimoto</last_name>
    </contact>
    <investigator>
      <last_name>Masahiro Kizaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital (Site 421)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuka Saito</last_name>
    </contact>
    <investigator>
      <last_name>Yukio Kobayashi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute of Medical Science, The University of Tokyo (Site 417)</name>
      <address>
        <city>Tokyo</city>
        <zip>108-8639</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minako Kono</last_name>
    </contact>
    <investigator>
      <last_name>Arinobu Tojo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital (Site 430)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Mae</last_name>
    </contact>
    <investigator>
      <last_name>Tetsuzo Tauchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital (Site 938)</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dong-Wook Kim, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bergens Universitetssjukhus (Site 690)</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingeborg Tennebekk Nessa</last_name>
      <phone>55973544</phone>
    </contact>
    <investigator>
      <last_name>Bjorn T Gjertsen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Malopolskie Medical Center (Site 546)</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Kowalowka</last_name>
      <phone>00 48 12 295 41 44</phone>
    </contact>
    <investigator>
      <last_name>Tomasz Sacha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii (Site 691)</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urszula Szustkiewicz</last_name>
      <phone>22 34-96-612</phone>
    </contact>
    <investigator>
      <last_name>Krzysztof Warzocha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Independent Public Clinical Hospital No. 1 in Wroclaw (Site 547)</name>
      <address>
        <city>Wrocław</city>
        <zip>50-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariusz Grajcar</last_name>
      <phone>48-71-7842697</phone>
    </contact>
    <investigator>
      <last_name>Ewa Medras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Uniwersytetu Medycznego w Łodzi (Site 550)</name>
      <address>
        <city>Łódź</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Przybysz</last_name>
      <phone>0048 42 689-51-91</phone>
    </contact>
    <investigator>
      <last_name>Tadeusz Robak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Lisboa (Site 545)</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Inacio</last_name>
      <phone>00351 21 722 9800</phone>
    </contact>
    <investigator>
      <last_name>Antonio M Almeida, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de S. João (Site 559)</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Ribeiro</last_name>
      <phone>00351 22 550 4463</phone>
    </contact>
    <investigator>
      <last_name>Manuel S Simões</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Clinical Hospital (Site 455)</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludmila Chervova</last_name>
      <phone>79511702167</phone>
    </contact>
    <investigator>
      <last_name>Marina Kosinova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Scientific Center (Site 453)</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galina Dudina</last_name>
      <phone>+7 916 650 85 77</phone>
    </contact>
    <investigator>
      <last_name>Mikhail Y Byakhov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haematological Scientific Center (Site 452)</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nemchenko Irina, MD</last_name>
      <phone>89165659371</phone>
    </contact>
    <investigator>
      <last_name>Anna Turkina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zelteer Anastasia</last_name>
      <phone>79604684666</phone>
    </contact>
    <investigator>
      <last_name>Yury Shatokhin, m.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Russian Research Institute of Haematology and Transfusiology</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Fominykh</last_name>
      <phone>7 921 386 7085</phone>
    </contact>
    <investigator>
      <last_name>Vasily Shuvaev, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution V. A. Almazov Federal North-West Medical (Site 454)</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Shakhomirova</last_name>
    </contact>
    <investigator>
      <last_name>Elza Lomaia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samara State Medical University (Site 699)</name>
      <address>
        <city>Samara</city>
        <zip>443079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ksenia V Naumova</last_name>
      <phone>8(846)264 79 72</phone>
    </contact>
    <investigator>
      <last_name>Igor Davydkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital (Site 939)</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Charles Chuah Thuan Heng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya (Site 698)</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Jimenez Velasco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic, Service de Hematologia (Site 963)</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francisco Cervantes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr Negrin (Site 692)</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Islas Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mireya A Lopez</last_name>
      <phone>0034928 440112</phone>
    </contact>
    <investigator>
      <last_name>Maria Teresa Gomez Casares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa, Hematology Servicem 2a Planta (Site 555)</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Luis Steegmann Olmedillas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal (Site 538)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valentin Garcia Gutierrez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia (Site 964)</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Carlos Hernandez Boluda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe (Site 666)</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Tordera</last_name>
      <phone>34 961 24 49 80</phone>
    </contact>
    <investigator>
      <last_name>Jaime Sanz Caballer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Uppsala (Site 945)</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aime Mukenyuzi</last_name>
      <phone>46186113456</phone>
    </contact>
    <investigator>
      <last_name>Ulla Olsson-Stromberg, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich (Site 562)</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabell Pieper-Scholz</last_name>
      <phone>0041 442559565</phone>
    </contact>
    <investigator>
      <last_name>Stefan Balabanov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital (Site 979)</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jih-Luh Tang, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow &amp; Clyde, The Beatson West of Scotland Cancer Centre (Site 797)</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Professor Tessa Holyoake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Liverpool University Hospital (Site 969)</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Professor Richard Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust (Site 693)</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Hugues de Lavallade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital (Site 967)</name>
      <address>
        <city>London</city>
        <zip>W120NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Storch</last_name>
      <phone>0044 (0) 20 331 34333</phone>
    </contact>
    <investigator>
      <last_name>Jane F Apperley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The New Castle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital (Site 970)</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai Kay Jones</last_name>
      <phone>191 213 8241</phone>
      <phone_ext>38241</phone_ext>
    </contact>
    <investigator>
      <last_name>Wendy Osborne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Centre for Clinical Haematology, Notthingham University Hospitals NHS Trust (Site 968)</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Scott</last_name>
      <phone>0115 9691169</phone>
      <phone_ext>59414</phone_ext>
    </contact>
    <investigator>
      <last_name>Jennifer Byrne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203469s009lbl.pdf</url>
    <description>Iclusig® (ponatinib) US Prescribing Information</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Phase Chronic Myeloid Leukemia</keyword>
  <keyword>Molecular Response</keyword>
  <keyword>CML</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Myeloproliferative Disorders</keyword>
  <keyword>Bone Marrow Diseases</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>CP-CML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

